Exosens stock
Price history
+11.36% over the period1 year: from €44.90 (November 20, 2025) to €50.00 (November 20, 2026), +11.36%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 20, 2026 | €50.00 |
| October 30, 2026 | €56.90 |
| September 30, 2026 | €59.80 |
| August 31, 2026 | €58.05 |
| July 31, 2026 | €57.20 |
| June 30, 2026 | €57.10 |
| May 29, 2026 | €68.15 |
| April 30, 2026 | €64.85 |
| March 31, 2026 | €61.20 |
| February 27, 2026 | €62.30 |
| January 30, 2026 | €53.90 |
| December 31, 2025 | €48.45 |
| November 28, 2025 | €41.95 |
| November 20, 2025 | €44.90 |
At a glance
The company
Develops and manufactures electro-optical technologies for defense, surveillance, life sciences, industrial and nuclear applications
Latest results
Quarter to September 30, 2026
TickerLandia's take on Exosens
- Pricier than similar companies: trailing 12-month P/E 119 vs 40 (+197%) in a group of 10.
- Strong point: Profitability (64/100 in its group). Weak point: Market momentum (27/100).
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−32.43% from the 52-week high
Analysts · 10 analysts
Average target€69.85+39.70% vs. price
Buy 8 · Hold 2 · Sell 0 · Buy
TickerLandia Fingerprint: Exosens
Compared with similar companies: weak momentum, high price, and high profitability.
Financials and price compared with 73 companies in the aerospace & defense industry, worldwide. Momentum and risk compared with 1,160 European stocks.
Pricehigh72
How much it costs relative to what it produces.
Metric Value Position in group P/E (trailing 12 months) 123.7 98 Forward P/E 21.3 53 EV/EBITDA 27.1 71 Price/book 5.87 59 Price/sales 5.25 79 Profitabilityhigh64
How much it earns on revenue and capital.
Metric Value Position in group Gross margin 60.1% 98 Net margin 6.0% 34 ROE 12.7% 36 ROA 6.2% 71 Operating margin 17.4% 80 Earnings stabilityaverage43
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 2.9% 50 Loss-making yearscounts in reverse: lower means more earnings stability 1 of 5 annual reports 37 Growthaverage48
How fast revenue and earnings are growing.
Metric Value Position in group Earnings growth (year over year) −45.10% 23 Revenue growth (year over year) +15.30% 45 Average revenue growth (3 years) +32.61% 76 Financial strengthaverage53
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Net debt/EBITDAcounts in reverse: lower means more financial strength 1.53 36 Interest coverage 8.61 58 Debt/equitycounts in reverse: lower means more financial strength 0.60 37 Current ratio 2.35 80 Dividendaverage49
How much it returns to shareholders, and for how long.
Metric Value Position in group Consecutive dividend years at least 2 years 27 Payout ratio 71.4% 95 Dividend yield 0.6% 23 Market momentumweak27
How the stock has moved compared with the market.
Metric Value Position in group Relative strength (3 months) −14.29% 16 Relative strength (6 months) −16.62% 24 1-year return +11.36% 55 Distance from 200-day average −16.92% 14 Riskaverage59
How much the price swings.
Metric Value Position in group Maximum drawdown (12 months) 31.4% 71 Beta (1 year) 0.42 21 Volatility (60 days) 43.0% 86
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 22, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
Exosens is pricier than similar companies
Exosens's P/E (trailing 12 months): 119.0, +197% against the median of a group of 10 similar companies (40.0).
Compared with 10 similar companies
| Metric | Exosens | Position in the group | Band |
|---|---|---|---|
| P/E (trailing 12 months) | 119.0 | High | |
| Forward P/E | 20.5 | Middle | |
| Operating margin | 17.4% | High | |
| ROE | 12.7% | Middle | |
| Debt/equity | 0.60 | Middle |
Grey band: the middle half of the group; tick: the median; dot: Exosens. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
€253.07M
Latest quarter · Q2 2026
Net income
€15.34M
Latest quarter · Q2 2026
Quarterly net margin
6.1%
Latest quarter · Q2 2026
Numbers and valuation
Full valuation- Market cap
- €2.53B
- P/E
- 119.0
- EPS
- €0.42
- Volume
- 98.86K
- Daily trading
- €4.97M
How Exosens is changing
All resultsRevenue grew 25.6% a year on average over the last 5 years
Operating margin rose from 15.0% to 22.2%
Profits turn into cash: free cash flow equal to 135% of net income
Returns
Exosens returns with dividends
€1,000 invested in Exosens 1 year ago, on November 20, 2025, would be worth €1,119 today with dividends reinvested: +11.89% in total, +11.89% per year. On price alone it would be €1,114 (+11.36%).
| Period | Exosens | CAC 40 | €1,000 becomes |
|---|---|---|---|
| 1 month | −12.97% | +1.14% | €870 |
| 6 months | −18.57% | −2.34% | €814 |
| Year to date | +3.20% | −2.72% | €1,032 |
| 1 year | +11.89% | −0.67% | €1,119 |
Over the last 6 months it has done better than 39% of the stocks in the Technology sector.
From 1 year up with dividends reinvested, before taxes; under a year price only. CAC 40: price only. Calculate your investment
The chart in detail
Exosens: technical analysis
Exosens is in a downtrend: the price is below its 50- and 200-session moving averages, and the 200-session average is falling. The price is 31.4% below its all-time closing high (€72.90, March 18, 2026).
- Trend
- Downward
- RSI (14 sessions)
- 35
- Between 30 and 70
- vs 200-session average
- −16.92%
Active signals
Close below the low of the previous 55 sessions.
Support and resistance
Price areas where Exosens has stopped several times in the last year. They describe the chart; they are not forecasts.
- Resistance€54.34+8.67%4 touches, last on October 8, 2026
- Resistance€52.70+5.40%2 touches, last on January 26, 2026
- Resistance€50.78+1.55%2 touches, last on June 26, 2026
- Last price€50.00
- No support below: the price is near the lows of the year
Volatility and risk
Over the last year it has moved less than the CAC 40.
- Beta (1 year) vs CAC 40
- 0.42
- Volatility (60 sessions, annualised)
- 43.0%
- Largest fall in the last year
- −31.41%
Close of November 20, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
The company
Exosens and its competitors
Its customers come from defense and surveillance, nuclear, industrial control, and life sciences and environment markets, and the company sells into France, the rest of Europe, North America, Asia and other international markets. Exosens designs, makes and sells electro-optical technologies organized in two segments: amplification, which covers image intensifier tubes, and detection and imaging, which spans cameras, sensors, imaging systems, and detectors for ions, electrons, photons and neutrons.
- Headquarters
- Mérignac, France
- Employees
- 2,000
- Founded
- 1937
- Chief executive
- Jerome Cerisier
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| ExosensEXENS | $2.78B | 17.4% | 119.0 | −18.57% |
| QinetiQ GroupQQ. | $3.24B | 12.5% | — | +6.67% |
| LisiFII | $3.3B | 9.8% | 35.1 | −1.72% |
| RENK GroupR3NK | $3.36B | 10.7% | 44.9 | −36.13% |
| Exail TechnologiesEXA | $2.35B | 7.4% | 25.9 | +2.69% |
| Theon InternationalTHEON | $2.33B | 24.4% | 16.5 | −15.74% |
Same industry or related industries, similar size. Compare Exosens with its competitors · Full profile
